ClinicalTrials.gg
RecruitingNCT06169163ViSONUpdated May 2, 2025

Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal Neoplasms

An observational study in Oesophageal Squamous Cell Carcinoma and Oesophageal Cancer, sponsored by Imperial College London. Recruiting at 13 sites in United Kingdom. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-05-02.

Sponsored by Imperial College London · Observational

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
518
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Esophageal Squamous Cell Carcinoma with a site in United Kingdom — 10 open to participants now, 11 under way, 1 of them phase 3. Esophageal Squamous Cell Carcinoma · United Kingdom.

Started
2023
the only one that year
Observational
4 of 29
2 open now
Primary completion
2026-11
later than 0 of 10 live
Registered
22nd of 29
by date
Lead sponsor
2 of 29
Imperial College London

Among the 29 studies in Esophageal Squamous Cell Carcinoma with a site in United Kingdom, this one is the only one that started in 2023, is one of 4 observational ones, reaches primary completion later than 0 of the 10 other live ones, and was the 22nd registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

10 of the 29 studies in Esophageal Squamous Cell Carcinoma with a site in United Kingdom are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Esophageal Squamous Cell Carcinoma with a site in United Kingdom, or all of them as a file.
02

Study summary

Oesophageal Squamous Cell Carcinoma (OSCC) is a cancer of the food pipe that affects around 2000 patients in the UK every year. It is often detected at an advanced stage, resulting in poor survival (5-year survival less than 20%). Early detection can improve survival (5-year survival >70%). Therefore, early detection is vital to improving survival.

There are no national screening guidelines, and an endoscopy (A camera test to look at the food pipe) is the only available test to detect OSCC.

Early detection of OSCC is challenging for many reasons. Firstly, early disease symptoms are non-specific, which patients often overlook. Secondly, 'Alarm' symptoms such as weight loss, difficulty swallowing or vomiting blood are signs of advanced stage. Lastly, endoscopy is an invasive test with associated risks and significant discomfort.

The investigators propose to develop a breath test for patients with non-specific symptoms. Breath testing has the ideal characteristics for a triage test because it is non-invasive, simple to perform, cost-effective and highly acceptable to patients. The test is based on identifying volatile organic compounds (VOCs, small molecules) that are produced by the cancer and released in breath.

The breath test will be offered by General Practitioners (GPs) to patients with non-specific symptoms. Those who test positive will be referred for an urgent camera test, and those who test negative can be reassured.

Read the detailed description

In this prospective multicentre case-control study, the investigators will recruit a total of 518 patients. These will be divided into the following groups:

  1. Cancer group (n=259): Patients with treatment naive, histopathology confirmed OSCC.
  2. Control group (n=259): Patients who have undergone or are undergoing an upper gastrointestinal (GI) endoscopy as part of their investigation for upper GI symptoms and are found to have either - (i) A normal upper GI tract or (ii) Benign upper GI disease.

Eligible and willing participants will be asked to provide two breath samples by exhaling into single-use breath collection bags. Using a custom designed gas sampling pump, the breath VOCs will be transferred onto thermal desorption (TD) tubes at a controlled flow rate. When the participants' breath sampling is complete, room air (Blank) samples will be taken onto additional TD tubes using the same process.

Once collected, the TD tubes will be transported to Imperial College London (The Hanna lab), where they will be analysed.

03

Conditions studied

  • Oesophageal Squamous Cell Carcinoma
  • Oesophageal Cancer

Keywords

  • Breath biomarker
  • Early detection
  • Oesophageal cancer
  • Oesophageal squamous cell cancer
  • Volatile organic compounds
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with treatment naïve OSCC will be identified via the weekly multidisciplinary team (MDT) meetings (OSCC group). Patients undergoing an OGD for upper GI symptoms will be identified using the National Health Services (NHS) trust booking systems (Control group).

Eligibility criteria

Inclusion Criteria: Participants with all the following characteristics will be eligible for inclusion in the study:

  1. Cancer cohort (n=259): Patients with treatment naïve, histopathology confirmed OSCC.
  2. Control cohort (n=259): Patients who have undergone or are undergoing an endoscopy (OGD) as part of their investigation for upper GI symptoms and are found to have either:

    • A normal upper gastrointestinal tract
    • Benign upper gastrointestinal disease

Exclusion Criteria: Participants with the following characteristics will not be eligible for inclusion in the study:

  1. Received some form of treatment (chemotherapy, radiotherapy, immunotherapy, endoscopic resection, or surgery) for OSCC
  2. History of another cancer in the last five years
  3. Non-squamous cell oesophageal cancer
  4. Barrett's oesophagus (with or without dysplasia)
  5. Previous oesophageal or gastric resection
  6. Unable to provide written consent or lack capacity.
  7. Pregnant women
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
518 participants (estimated)
Patient registry
No

Groups and cohorts

  • OSCC group

    Patients with histopathology confirmed, treatment naive OSCC

    Other: Exhaled breath sampling

  • Non-cancer controls

    Patients who are undergoing an endoscopy for non-specific upper gastrointestinal (GI) symptoms and are shown to have either: 1. A healthy upper GI tract 2. Benign upper gastrointestinal disease

    Other: Exhaled breath sampling

Interventions

  • OtherExhaled breath sampling

    Participants will maintain a clear fluid diet for a minimum of 6 hours prior to breath collection. Participants will be asked to provide a breath sample by exhaling into single-use breath collection bags. Using a custom designed gas sampling pump, the breath VOCs will be transferred onto TD tubes at a controlled flow rate. This breath sampling procedure will be repeated once. When the participants' breath sampling is complete, room air (Blank) samples must be taken onto additional TD tubes using the same procedure. The TD tubes will be sealed with long-term storage caps using the CapLok Tool.

06

What researchers measure

Primary outcomes

  1. To develop a breath test for detection of OSCC

    The investigators hypothesise that breath VOCs in OSCC are unique and different to those in non-cancer patients. Replicate breath samples will be analysed by two independent assays using different Thermal Desorption - Gas Chromatography - Time of Flight Mass Spectrometry (TD-GC-TOF-MS) instruments. One assay will use a mid-polar, and the other a polar column stationary phase for optimal determination of VOC chemical classes. The samples will then be recollected and analysed by two-dimensional (2D) TD-GC-TOF-MS for robust VOC identification. Confirming the identity of the top VOCs driving the model will provide chemical validation. Data obtained will be used to refine the model using molecular network analysis. Statistical methods will estimate the probability of OSCC as a function of measured VOCs. Calibrations and method validation will be used to assess and correct for discrimination.

    Time frame: 36 months

Secondary outcomes

  1. To evaluate the effects of known confounding variables on the target VOCs in OSCC

    To develop this clinical triage test, the investigators will use logistic regression modelling. They will assess the linearity of relationships between OSCC risk and continuous variables and explore categorical variables and two-way interactions. Inclusion of patient characteristics (e.g., age, gender, alcohol use and smoking), clinical variables (e.g., symptoms) and VOCs in the model will be determined using a combination of statistical significance (Wald p\<0.05), size of the model coefficients and clinical opinion, drawing on contemporary methods for clinical prediction rules. The investigators will use model reduction techniques such as the LASSO (least absolute shrinkage and selection operator) or Harrell's step-down approach to prevent over-fitting. They will also assess optimism. If there is missing data, the investigators will apply multiple imputation techniques.

    Time frame: 36 months

07

Study locations

8 of 13 sites recruiting
  • Imperial College Healthcare NHS Trust
    London, Greater London W12 0NN, United Kingdom
    Recruiting
  • Hull University Teaching Hospitals NHS Trust
    Cottingham, Hull, United Kingdom
    Recruiting
    • Terence Lo · Principal investigator
  • Cardiff and Vale University Health Board
    Cardiff, United Kingdom
    Not yet recruiting
    • Tarig Abdelrahman · Principal investigator
  • Velindre NHS Trust
    Cardiff, United Kingdom
    Not yet recruiting
    • Betsan Thomas · Principal investigator
  • University Hospitals Coventry and Warwickshire NHS Trust
    Coventry, United Kingdom
    Recruiting
    • Martin Scott-Brown · Principal investigator
  • University Hospitals of Leicester NHS Foundation Trust
    Leicester, United Kingdom
    Recruiting
    • Alex Boddy · Principal investigator
  • Liverpool University Hospitals NHS Foundation Trust
    Liverpool, United Kingdom
    Not yet recruiting
    • Andrew Moore · Principal investigator
  • The Clatterbridge Cancer Centre NHS Foundation Trust
    Liverpool, United Kingdom
    Recruiting
    • Alia Alchawaf · Principal investigator
  • Bedfordshire Hospitals NHS Foundation Trust
    Luton, United Kingdom
    Not yet recruiting
    • Periyathambi Jambulingam · Principal investigator
  • Newcastle Upon Tyne Hospitals NHS Trust
    Newcastle, United Kingdom
    Recruiting
    • Shajahan Wahed · Principal investigator
  • Norfolk and Norwich University Hospitals NHS Foundation Trust
    Norwich, United Kingdom
    Recruiting
    • Bhaskar Kumar · Principal investigator
  • Oxford University Hospitals NHS Trust
    Oxford, United Kingdom
    Recruiting
    • Somnath Mukherjee · Principal investigator
  • Portsmouth Hospitals University NHS Trust
    Portsmouth, United Kingdom
    Not yet recruiting
    • Philip Pucher · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Nov 2026, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2023
First posted
Dec 13, 2023
StartActual
Dec 1, 2023
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2026
Last update
May 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06169163
Collaborators
Imperial College Healthcare NHS Trust, Hull University Teaching Hospitals NHS Trust, Norfolk and Norwich University Hospitals NHS Foundation Trust, University Hospitals Coventry and Warwickshire NHS Trust, Oxford University Hospitals NHS Trust, Velindre NHS Trust, Cardiff and Vale University Health Board, Newcastle-upon-Tyne Hospitals NHS Trust, Liverpool University Hospitals NHS Foundation Trust, Bedfordshire Hospitals NHS Foundation Trust, University Hospitals, Leicester, The Clatterbridge Cancer Centre NHS Foundation Trust, Portsmouth Hospitals NHS Trust, University Hospital Plymouth NHS Trust, NHS Tayside, NHS Highlands, The Christie NHS Foundation Trust, North Cumbria University Hospitals NHS Trust, Maidstone & Tunbridge Wells NHS Trust, University Hospitals of Derby and Burton NHS Foundation Trust, Bradford Teaching Hospitals NHS Foundation Trust, East and North Hertfordshire NHS Trust
Responsible party
Sponsor
First posted
Dec 13, 2023
Start date
Dec 1, 2023
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 2, 2025

Study contacts

Sameera Sharma, MBBS; MRCS
Contact
vison@imperial.ac.uk
07576583519

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion